This company seems to have been delisted
Reason: Acquired by AbbVie
Last recorded trade on: April 12, 2024
Source: https://news.abbvie.com/2024-02-12-AbbVie-Completes-Acquisition-of-ImmunoGen
Reason: Acquired by AbbVie
Last recorded trade on: April 12, 2024
Source: https://news.abbvie.com/2024-02-12-AbbVie-Completes-Acquisition-of-ImmunoGen
ImmunoGen
IMGN
S$39.79
Share price
0.00%
Change (1 day)
120.97%
Change (1 year)
Categories
ImmunoGen (IMGN) - Total assets
Total assets on the balance sheet as of September 2023 : S$1.04 Billion
According to ImmunoGen 's latest financial reports the company's total assets are S$1.04 Billion. A company’s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
ImmunoGen - Total assets on balance sheet (from 2001 to 2023)
Total assets by year
| Year | Total assets | Change |
|---|---|---|
| 2022-12-31 | S$0.46 B | -34.19% |
| 2021-12-31 | S$0.71 B | 51.32% |
| 2020-12-31 | S$0.46 B | 48.1% |
| 2019-12-31 | S$0.31 B | -21.4% |
| 2018-12-31 | S$0.40 B | 2.39% |
| 2017-12-31 | S$0.39 B | |
| 2016-06-30 | S$0.37 B | -9.43% |
| 2015-06-30 | S$0.41 B | 101.52% |
| 2014-06-30 | S$0.20 B | -23.96% |
| 2013-06-30 | S$0.27 B | 18.64% |
| 2012-06-30 | S$0.22 B | -14.46% |
| 2011-06-30 | S$0.26 B | 40.18% |
| 2010-06-30 | S$0.19 B | 30.98% |
| 2009-06-30 | S$0.14 B | 28.26% |
| 2008-06-30 | S$0.11 B | -8.06% |
| 2007-06-30 | S$0.12 B | -17.66% |
| 2006-06-30 | S$0.14 B | -19.66% |
| 2005-06-30 | S$0.18 B | -11.29% |
| 2004-06-30 | S$0.21 B | 1.44% |
| 2003-06-30 | S$0.20 B | -22.94% |
| 2002-06-30 | S$0.26 B | -7.29% |
| 2001-06-30 | S$0.29 B |
Total Assets for similar companies or competitors
| Company | Total assets | differencediff. | Country |
|---|---|---|---|
 Seagen
SGEN | S$4.63 B | 342.07% | 🇺🇸 USA |
 Amgen AMGN | S$113.85 B | 10,770.56% | 🇺🇸 USA |
 Eli Lilly LLY | S$113.88 B | 10,773.21% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | S$117.75 B | 11,142.78% | 🇺🇸 USA |
 Johnson & Johnson JNJ | S$246.73 B | 23,458.05% | 🇺🇸 USA |
 Pfizer PFE | S$265.02 B | 25,204.43% | 🇺🇸 USA |
 Novartis NVS | S$127.32 B | 12,056.78% | 🇨🇭 Switzerland |
 Sanofi SNY | S$181.78 B | 17,256.99% | 🇫🇷 France |